Diagnostics
-
Devices & Diagnostics, Diagnostics
GRIP Molecular goes with graphene to put powerful diagnostics into patient hands
Diagnostics startup GRIP Molecular is developing an at-home test for Covid-19 and other respiratory infections. The technology builds on advances from several fields, including the discovery of graphene, a material that offers biocompatibility and conductivity.
-
Smartphones could be used to detect depression, Verily finds
A study published by Verily researchers showed that some smartphone metrics, such as sentiment in weekly voice diaries, matched up with the severity of users’ depression as determined by PHQ-9 scores. Even if these technologies could be used to track mental health, it’s not clear how they will fit into physician workflows or how comfortable people will be using their smartphones in this way.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
Portable diagnostics company Cue raises $200M in IPO
The diagnostics company currently has an authorized at-home Covid-19 test, and plans to expand into flu tests and other diagnostics. After pricing its stock at $16 per share, it climbed to $20 on Friday.
-
MedCity Influencers, Diagnostics
How self-diagnostics can cut healthcare costs and save Lives
The call to action is that point-of-care testing needs to move to the home and it needs to be supported by a Medicaid or Medicare billing code to support insurance coverage and payment for the testing.
-
Mammoth Bio’s massive $195M financing makes the CRISPR company a unicorn
Mammoth Biosciences is applying CRISPR technology to both diagnostics and therapeutics. With the new financing, CEO Trevor Martin said that the company is looking ahead toward clinical trials and perhaps partnerships with larger companies.
-
Buoyed by Covid-19 tests, Cue files for IPO
The San Diego-based company began marketing its first product, a portable Covid-19 test, after receiving an emergency use authorization last year. Now, it’s filing the initial paperwork to go public as it scales up manufacturing.
-
Artificial Intelligence, Devices & Diagnostics, Diagnostics, Employee Benefits, Health IT, Health Services, Health Tech, Payers, Startups, SYN
Finding healthcare sales leads just got easier
The Knowledge Hub from MedCity News is designed to help you get targeted healthcare leads and scale your business, at no upfront cost to you.
-
Avoid surprises by preparing to implement the No Surprises Act
The clock is ticking down for payers and providers to comply with the No Surprises Act, which protects patients from balance billing for the most common ancillary medical services. Here’s how to get your ducks in a row.
-
Artificial Intelligence, BioPharma, Devices & Diagnostics, Diagnostics, Health IT, Health Services, SYN
Finding healthcare sales leads just got easier
MedCity News has launched the Knowledge Hub to help you get targeted healthcare leads and scale your business, at no upfront cost to you.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Illumina’s Grail buyout beats deadline, but legal and regulatory hurdles remain
In closing its Grail acquisition before U.S. and European regulators sign off, Illumina is taking a chance the deal will pass regulatory muster. It’s a potentially pricey gambit, as Illumina could face fines for its early action and there are no assurances that regulators will agree that the deal is not anticompetitive.
-
How hc1 is generating actionable healthcare insights to support precision medicine
At the intersection of health tech and diagnostics, hc1’s CEO Brad Bostic talked about the company’s origins and how it works with medical laboratories, hospitals and health plans.
-
BCBS of Kansas City sues Covid-19 testing provider over alleged price gouging
GS Labs, a Covid-19 testing provider, has submitted over $9.2 million in claims to the insurer as a result of its grossly inflated prices, the lawsuit states. The testing company rejected the claims, saying its “prices accurately reflect the level of service” it provides.
-
MedCity Influencers, Diagnostics
Would Illumina’s acquisition of GRAIL constrict the expansion of the liquid biopsy space?
The Federal Trade Commission and the European Union are reviewing the soundness of this acquisition. But if Illumina acquires Grail, the company that it spawned back in January 2016, will it squeeze the nascent liquid biopsy market?
-
Diagnostics, MedCity Influencers, SYN
Real-time Interpretation: The next frontier in radiology AI
To date, AI has demonstrated value in its ability to handle asynchronous tasks such as image triage and detection. What’s even more interesting is the potential to enhance real-time image interpretation by giving the computer context that lets it work with radiologists instead of trying to replace them.
-
PacBio’s $600M Omniome buyout brings together long & short of DNA sequencing
DNA sequencing company Pacific Biosciences has reached a $600 million agreement to acquire Omniome, a startup with complementary sequencing technology. The cash and stock deal comes about 18 months after antitrust concerns led PacBio and sequencing giant Illumina to terminate their tie-up.
Promoted
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
